Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

NCT02501096 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT02501096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02501096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 22, 2015
Completion date
July 11, 2022
Enrollment
357 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

tumors